Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor |
Ann & Robert H. Lurie Children’s Hospital of Chicago / Rintaro Hashizume, MD/PhD |
Reach Grants |
2018 |
Illinois |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma |
Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD |
Reach Grants |
2021 |
Georgia |
Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas |
New York University School of Medicine / Danny Reinberg, PhD |
Reach Grants |
2019 |
New York |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG |
The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD |
Reach Grants |
2022 |
Michigan |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor |
Baylor College of Medicine / William Decker, PhD |
Reach Grants |
2013 |
Texas |